The discriminative stimulus effects of mecamylamine in nicotine-treated and untreated rhesus monkeys

Colin S. Cunningham, Megan J. Moerke, Lance R. McMahon

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The extent to which chronic nicotine treatment can alter the effects of the nicotinic acetylcholine receptor antagonist mecamylamine, and whether those effects can be attenuated by nicotine have not been clearly established in the literature. Here, the discriminative stimulus effects of mecamylamine were compared between one group of rhesus monkeys receiving a continuous infusion of nicotine base (5.6mg/kg/day subcutaneously) and another group of monkeys not receiving nicotine treatment. Both groups responded under a fixed ratio 5 schedule of stimulus-shock termination. Stimulus control was obtained at doses of 1.78mg/kg mecamylamine in monkeys receiving continuous nicotine and 5.6mg/kg mecamylamine in monkeys not receiving continuous nicotine treatment. Nicotine did not attenuate the discriminative stimulus effects of mecamylamine in either group. Discontinuation of continuous nicotine produced responding on the mecamylamine lever within 24h in some but not all monkeys. This may indicate a qualitative difference in the discriminative stimulus effects of mecamylamine between groups, perhaps reflecting antagonism of nicotine and nicotine withdrawal in monkeys receiving continuous nicotine. The failure of nicotine to reverse the effects of mecamylamine is consistent with a noncompetitive interaction at nicotinic acetylcholine receptors and indicates that mecamylamine-induced withdrawal cannot be readily modified by nicotine.

Original languageEnglish (US)
Pages (from-to)296-305
Number of pages10
JournalBehavioural Pharmacology
Volume25
Issue number4
DOIs
StatePublished - 2014

Fingerprint

Mecamylamine
Macaca mulatta
Nicotine
Haplorhini
Nicotinic Receptors
Cholinergic Antagonists

Keywords

  • dependence
  • drug discrimination
  • mecamylamine
  • nicotine
  • rhesus
  • withdrawal

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health
  • Medicine(all)

Cite this

The discriminative stimulus effects of mecamylamine in nicotine-treated and untreated rhesus monkeys. / Cunningham, Colin S.; Moerke, Megan J.; McMahon, Lance R.

In: Behavioural Pharmacology, Vol. 25, No. 4, 2014, p. 296-305.

Research output: Contribution to journalArticle

Cunningham, Colin S. ; Moerke, Megan J. ; McMahon, Lance R. / The discriminative stimulus effects of mecamylamine in nicotine-treated and untreated rhesus monkeys. In: Behavioural Pharmacology. 2014 ; Vol. 25, No. 4. pp. 296-305.
@article{6ef321fa436646bd87c263289b67169b,
title = "The discriminative stimulus effects of mecamylamine in nicotine-treated and untreated rhesus monkeys",
abstract = "The extent to which chronic nicotine treatment can alter the effects of the nicotinic acetylcholine receptor antagonist mecamylamine, and whether those effects can be attenuated by nicotine have not been clearly established in the literature. Here, the discriminative stimulus effects of mecamylamine were compared between one group of rhesus monkeys receiving a continuous infusion of nicotine base (5.6mg/kg/day subcutaneously) and another group of monkeys not receiving nicotine treatment. Both groups responded under a fixed ratio 5 schedule of stimulus-shock termination. Stimulus control was obtained at doses of 1.78mg/kg mecamylamine in monkeys receiving continuous nicotine and 5.6mg/kg mecamylamine in monkeys not receiving continuous nicotine treatment. Nicotine did not attenuate the discriminative stimulus effects of mecamylamine in either group. Discontinuation of continuous nicotine produced responding on the mecamylamine lever within 24h in some but not all monkeys. This may indicate a qualitative difference in the discriminative stimulus effects of mecamylamine between groups, perhaps reflecting antagonism of nicotine and nicotine withdrawal in monkeys receiving continuous nicotine. The failure of nicotine to reverse the effects of mecamylamine is consistent with a noncompetitive interaction at nicotinic acetylcholine receptors and indicates that mecamylamine-induced withdrawal cannot be readily modified by nicotine.",
keywords = "dependence, drug discrimination, mecamylamine, nicotine, rhesus, withdrawal",
author = "Cunningham, {Colin S.} and Moerke, {Megan J.} and McMahon, {Lance R.}",
year = "2014",
doi = "10.1097/FBP.0000000000000054",
language = "English (US)",
volume = "25",
pages = "296--305",
journal = "Behavioural Pharmacology",
issn = "0955-8810",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - The discriminative stimulus effects of mecamylamine in nicotine-treated and untreated rhesus monkeys

AU - Cunningham, Colin S.

AU - Moerke, Megan J.

AU - McMahon, Lance R.

PY - 2014

Y1 - 2014

N2 - The extent to which chronic nicotine treatment can alter the effects of the nicotinic acetylcholine receptor antagonist mecamylamine, and whether those effects can be attenuated by nicotine have not been clearly established in the literature. Here, the discriminative stimulus effects of mecamylamine were compared between one group of rhesus monkeys receiving a continuous infusion of nicotine base (5.6mg/kg/day subcutaneously) and another group of monkeys not receiving nicotine treatment. Both groups responded under a fixed ratio 5 schedule of stimulus-shock termination. Stimulus control was obtained at doses of 1.78mg/kg mecamylamine in monkeys receiving continuous nicotine and 5.6mg/kg mecamylamine in monkeys not receiving continuous nicotine treatment. Nicotine did not attenuate the discriminative stimulus effects of mecamylamine in either group. Discontinuation of continuous nicotine produced responding on the mecamylamine lever within 24h in some but not all monkeys. This may indicate a qualitative difference in the discriminative stimulus effects of mecamylamine between groups, perhaps reflecting antagonism of nicotine and nicotine withdrawal in monkeys receiving continuous nicotine. The failure of nicotine to reverse the effects of mecamylamine is consistent with a noncompetitive interaction at nicotinic acetylcholine receptors and indicates that mecamylamine-induced withdrawal cannot be readily modified by nicotine.

AB - The extent to which chronic nicotine treatment can alter the effects of the nicotinic acetylcholine receptor antagonist mecamylamine, and whether those effects can be attenuated by nicotine have not been clearly established in the literature. Here, the discriminative stimulus effects of mecamylamine were compared between one group of rhesus monkeys receiving a continuous infusion of nicotine base (5.6mg/kg/day subcutaneously) and another group of monkeys not receiving nicotine treatment. Both groups responded under a fixed ratio 5 schedule of stimulus-shock termination. Stimulus control was obtained at doses of 1.78mg/kg mecamylamine in monkeys receiving continuous nicotine and 5.6mg/kg mecamylamine in monkeys not receiving continuous nicotine treatment. Nicotine did not attenuate the discriminative stimulus effects of mecamylamine in either group. Discontinuation of continuous nicotine produced responding on the mecamylamine lever within 24h in some but not all monkeys. This may indicate a qualitative difference in the discriminative stimulus effects of mecamylamine between groups, perhaps reflecting antagonism of nicotine and nicotine withdrawal in monkeys receiving continuous nicotine. The failure of nicotine to reverse the effects of mecamylamine is consistent with a noncompetitive interaction at nicotinic acetylcholine receptors and indicates that mecamylamine-induced withdrawal cannot be readily modified by nicotine.

KW - dependence

KW - drug discrimination

KW - mecamylamine

KW - nicotine

KW - rhesus

KW - withdrawal

UR - http://www.scopus.com/inward/record.url?scp=84904195636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904195636&partnerID=8YFLogxK

U2 - 10.1097/FBP.0000000000000054

DO - 10.1097/FBP.0000000000000054

M3 - Article

VL - 25

SP - 296

EP - 305

JO - Behavioural Pharmacology

JF - Behavioural Pharmacology

SN - 0955-8810

IS - 4

ER -